For your adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment
DOPTELET® (avatrombopag): ONE DOSAGE STRENGTH HELPS MAKE TITRATION MANAGEABLE FOR YOU AND YOUR PATIENTS1
Titrate up or down as necessary, based on platelet count (see dosing table below for titration criteria)
After initiating therapy with DOPTELET, assess platelet counts weekly until a stable platelet count of ≥50x109/L has been achieved, and then obtain platelet counts monthly thereafter. Obtain platelet counts weekly for at least 4 weeks following discontinuation of DOPTELET.
TARGET THE RIGHT RESPONSE FOR YOUR PATIENT1
Initial dosing: Start with 1 tablet (20 mg) once daily with food, then dose-adjust if needed based on platelet count.
DOPTELET® (avatrombopag) dosing table
|PLATELET COUNT (×109/L)||DOSE ADJUSTMENT OR ACTION|
|Less than 50 after at least 2 weeks of DOPTELET||
|Between 200 and 400||
|Greater than 400||
|Less than 50 after
4 weeks of DOPTELET
40 mg once daily
|Greater than 400 after
2 weeks of DOPTELET
20 mg weekly
1. DOPTELET [package insert]. Durham, NC: Dova Pharmaceuticals, Inc.